Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT ...
Monitoring treatment response in breast cancer is of great importance and FDG PET has demonstrated its utility in this indication. FDG PET must be performed in patients with advanced disease treated ...
Pretreatment 18 F-FDG PET/CT scans from three study populations (N = 100, N = 39, N = 70) were used, comprising two single-institutional protocols and one publicly available data set. A clinician (V.J ...
Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001). This is an ASCO Meeting Abstract from the 2023 ASCO ...
Reston, Va.—Seven medical imaging groups wrote a joint letter to the Centers for Medicare and Medicaid Services (CMS) to formally request coverage of two fluorodeoxyglucose (FDG) positron emission ...
Expert Rev Anticancer Ther. 2009;9(1):75-96. Based on the available data, FDG-PET alone appears to be of limited use in differentiating tumors of low malignant potential from benign tumors and ovarian ...
At the San Antonio Breast Cancer Symposium, Jennifer Specht, MD, of the University of Washington and Fred Hutch Cancer Center, Seattle, presented results from the ECOG-ACRIN FEATURE trial, a phase II ...
Reston, VA – When developing a treatment plan for cervical cancer, it is important to be able to determine a patient's prognosis, ideally at the time of diagnosis. Existing methods to arrive at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results